Trials / Completed
CompletedNCT02335983
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carfilzomib | Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle. |
| DRUG | Lenalidomide | Administered orally once daily on days 1-21 of each 28-day cycle. |
| DRUG | Dexamethasone | Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8. |
Timeline
- Start date
- 2015-04-30
- Primary completion
- 2019-10-28
- Completion
- 2019-10-28
- First posted
- 2015-01-12
- Last updated
- 2020-11-06
- Results posted
- 2020-11-06
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02335983. Inclusion in this directory is not an endorsement.